S&P 500   5,251.81 (+0.06%)
DOW   39,741.24 (-0.05%)
QQQ   444.33 (-0.11%)
AAPL   171.29 (-1.17%)
MSFT   420.79 (-0.15%)
META   489.85 (-0.81%)
GOOGL   150.66 (-0.14%)
AMZN   181.35 (+0.85%)
TSLA   176.85 (-1.66%)
NVDA   905.92 (+0.38%)
NIO   4.59 (-1.71%)
AMD   182.39 (+1.56%)
BABA   72.33 (+1.03%)
T   17.55 (+0.00%)
F   13.18 (+0.92%)
MU   118.44 (-0.59%)
CGC   9.11 (-4.61%)
GE   176.24 (-2.15%)
DIS   122.76 (+1.47%)
AMC   3.77 (-13.13%)
PFE   27.86 (+0.29%)
PYPL   66.74 (+0.26%)
XOM   115.40 (+0.37%)
S&P 500   5,251.81 (+0.06%)
DOW   39,741.24 (-0.05%)
QQQ   444.33 (-0.11%)
AAPL   171.29 (-1.17%)
MSFT   420.79 (-0.15%)
META   489.85 (-0.81%)
GOOGL   150.66 (-0.14%)
AMZN   181.35 (+0.85%)
TSLA   176.85 (-1.66%)
NVDA   905.92 (+0.38%)
NIO   4.59 (-1.71%)
AMD   182.39 (+1.56%)
BABA   72.33 (+1.03%)
T   17.55 (+0.00%)
F   13.18 (+0.92%)
MU   118.44 (-0.59%)
CGC   9.11 (-4.61%)
GE   176.24 (-2.15%)
DIS   122.76 (+1.47%)
AMC   3.77 (-13.13%)
PFE   27.86 (+0.29%)
PYPL   66.74 (+0.26%)
XOM   115.40 (+0.37%)
S&P 500   5,251.81 (+0.06%)
DOW   39,741.24 (-0.05%)
QQQ   444.33 (-0.11%)
AAPL   171.29 (-1.17%)
MSFT   420.79 (-0.15%)
META   489.85 (-0.81%)
GOOGL   150.66 (-0.14%)
AMZN   181.35 (+0.85%)
TSLA   176.85 (-1.66%)
NVDA   905.92 (+0.38%)
NIO   4.59 (-1.71%)
AMD   182.39 (+1.56%)
BABA   72.33 (+1.03%)
T   17.55 (+0.00%)
F   13.18 (+0.92%)
MU   118.44 (-0.59%)
CGC   9.11 (-4.61%)
GE   176.24 (-2.15%)
DIS   122.76 (+1.47%)
AMC   3.77 (-13.13%)
PFE   27.86 (+0.29%)
PYPL   66.74 (+0.26%)
XOM   115.40 (+0.37%)
S&P 500   5,251.81 (+0.06%)
DOW   39,741.24 (-0.05%)
QQQ   444.33 (-0.11%)
AAPL   171.29 (-1.17%)
MSFT   420.79 (-0.15%)
META   489.85 (-0.81%)
GOOGL   150.66 (-0.14%)
AMZN   181.35 (+0.85%)
TSLA   176.85 (-1.66%)
NVDA   905.92 (+0.38%)
NIO   4.59 (-1.71%)
AMD   182.39 (+1.56%)
BABA   72.33 (+1.03%)
T   17.55 (+0.00%)
F   13.18 (+0.92%)
MU   118.44 (-0.59%)
CGC   9.11 (-4.61%)
GE   176.24 (-2.15%)
DIS   122.76 (+1.47%)
AMC   3.77 (-13.13%)
PFE   27.86 (+0.29%)
PYPL   66.74 (+0.26%)
XOM   115.40 (+0.37%)
NASDAQ:AMPH

Amphastar Pharmaceuticals (AMPH) Stock Price, News & Analysis

$44.80
+1.28 (+2.94%)
(As of 10:28 AM ET)
Today's Range
$43.76
$44.83
50-Day Range
$42.85
$56.43
52-Week Range
$35.62
$67.66
Volume
49,422 shs
Average Volume
483,561 shs
Market Capitalization
$2.15 billion
P/E Ratio
17.36
Dividend Yield
N/A
Price Target
$66.00

Amphastar Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
51.7% Upside
$66.00 Price Target
Short Interest
Bearish
10.42% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.21
Upright™ Environmental Score
News Sentiment
1.11mentions of Amphastar Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$15.72 M Sold Last Quarter
Proj. Earnings Growth
17.19%
From $3.49 to $4.09 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.95 out of 5 stars

Medical Sector

16th out of 939 stocks

Pharmaceutical Preparations Industry

8th out of 434 stocks

AMPH stock logo

About Amphastar Pharmaceuticals Stock (NASDAQ:AMPH)

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

AMPH Stock Price History

AMPH Stock News Headlines

Warning: this could blow your mind
Buckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…
AMPH Apr 2024 65.000 call
AMPH Apr 2024 60.000 put
This consistently signaled gains of 453%... 610%... and even 1036%...
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
LLY Mar 2024 980.000 call
Q4 2023 Amphastar Pharmaceuticals Inc Earnings Call
Here's what Wall Street expects from Amphastar Pharmaceuticals's earnings
Amphastar Pharmaceuticals, Inc.
Amphastar- Five Star Trade in Biotech
Amphastar Pharmaceuticals Inc.
See More Headlines
Receive AMPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amphastar Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
3/28/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AMPH
Employees
1,761
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$66.00
High Stock Price Target
$71.00
Low Stock Price Target
$60.00
Potential Upside/Downside
+47.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$137.54 million
Pretax Margin
26.59%

Debt

Sales & Book Value

Annual Sales
$644.40 million
Cash Flow
$4.53 per share
Book Value
$13.35 per share

Miscellaneous

Free Float
34,437,000
Market Cap
$2.15 billion
Optionable
Optionable
Beta
0.85
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

AMPH Stock Analysis - Frequently Asked Questions

Should I buy or sell Amphastar Pharmaceuticals stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amphastar Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AMPH shares.
View AMPH analyst ratings
or view top-rated stocks.

What is Amphastar Pharmaceuticals' stock price target for 2024?

3 equities research analysts have issued 12 month price objectives for Amphastar Pharmaceuticals' shares. Their AMPH share price targets range from $60.00 to $71.00. On average, they predict the company's stock price to reach $66.00 in the next year. This suggests a possible upside of 51.7% from the stock's current price.
View analysts price targets for AMPH
or view top-rated stocks among Wall Street analysts.

How have AMPH shares performed in 2024?

Amphastar Pharmaceuticals' stock was trading at $61.85 on January 1st, 2024. Since then, AMPH stock has decreased by 29.6% and is now trading at $43.52.
View the best growth stocks for 2024 here
.

When is Amphastar Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our AMPH earnings forecast
.

How were Amphastar Pharmaceuticals' earnings last quarter?

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) released its quarterly earnings data on Wednesday, February, 28th. The company reported $0.81 earnings per share for the quarter, missing the consensus estimate of $0.84 by $0.03. The business had revenue of $178.11 million for the quarter, compared to the consensus estimate of $174.90 million. Amphastar Pharmaceuticals had a net margin of 21.34% and a trailing twelve-month return on equity of 26.95%.

What is Jack Y. Zhang's approval rating as Amphastar Pharmaceuticals' CEO?

35 employees have rated Amphastar Pharmaceuticals Chief Executive Officer Jack Y. Zhang on Glassdoor.com. Jack Y. Zhang has an approval rating of 35% among the company's employees. This puts Jack Y. Zhang in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 48.0% of employees surveyed would recommend working at Amphastar Pharmaceuticals to a friend.

What other stocks do shareholders of Amphastar Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amphastar Pharmaceuticals investors own include Cara Therapeutics (CARA), Gilead Sciences (GILD), Amicus Therapeutics (FOLD), Exelixis (EXEL), CNX Resources (CNX), Immunomedics (IMMU), AbbVie (ABBV), Cellectis (CLLS), Clovis Oncology (CLVS) and Galectin Therapeutics (GALT).

Who are Amphastar Pharmaceuticals' major shareholders?

Amphastar Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Federated Hermes Inc. (6.83%), Vanguard Group Inc. (5.88%), Vanguard Group Inc. (5.85%), Dimensional Fund Advisors LP (2.80%), TD Asset Management Inc (1.66%) and Epoch Investment Partners Inc. (1.24%). Insiders that own company stock include Diane G Gerst, Floyd F Petersen, Howard Lee, Jack Y Zhang, Mary Z Luo, Michael A Zasloff, Richard K Prins, Richard Koo, Rong Zhou, William J Peters and Yakob Liawatidewi.
View institutional ownership trends
.

How do I buy shares of Amphastar Pharmaceuticals?

Shares of AMPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AMPH) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners